← Leaderboards
Cameron Robert Currie
University Of Wisconsin-Madison
$16,716,349
Attributed
$23,522,948
Total exposure
12
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.9M · FY2010–22$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$39,763,972 · 13
By mechanism
U19$37,284,343 · 12
RC4$2,479,629 · 1
Top collaborators
- David R Andes25 shared
- Jon Clardy5 shared
- Michael A Hoffman5 shared
Most similar at University Of Wisconsin-Madison
Same institution · by research overlap
- Bruce Steven Klein$36,349,356
- Timothy S Bugni$14,214,749
- Elizabeth A Hussa$92,824
- Jerald C Ensign$5,702
- Heidi Goodrich-Blair$1,532,897
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseDrug DiscoveryAntimicrobialAntimicrobial DrugPathogenSourceCommunitiesPharmaceutical PreparationsFungusDrug ResistanceLeadEnvironmentResistanceBacteriaCollaborationsAntifungal AgentsCommunicable DiseasesIn VitroInnovationProductionSmall MoleculeNatural ProductsAnti-Bacterial AgentsScreening
Grant awards (50)
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses$922,907
U19 · FY2022 · AI · contact PI
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses$1,061,111
U19 · FY2021 · AI · contact PI
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses$1,142,106
U19 · FY2020 · AI · contact PI
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses$1,057,133
U19 · FY2019 · AI · contact PI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities$3,097,773
U19 · FY2018 · AI
In Vitro Core$670,175
U19 · FY2018 · AI
Discovering Antimicrobial Drugs from Symbiotic Actinobacteria from Terrestrial$508,653
U19 · FY2018 · AI · contact PI
Metabolomics driven discovery of drug leads from symbiotic bacteria$504,183
U19 · FY2018 · AI
Identification of novel secondary metabolites produced by symbiotic Proteobacte$475,202
U19 · FY2018 · AI
Mechanism of Action$463,540
U19 · FY2018 · AI
In Vivo CORE$335,448
U19 · FY2018 · AI
Admin-Core-001$140,572
U19 · FY2018 · AI
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates$133,826
U19 · FY2018 · TW · contact PI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities$3,190,133
U19 · FY2017 · AI
In Vitro Core$658,181
U19 · FY2017 · AI
Discovering Antimicrobial Drugs from Symbiotic Actinobacteria from Terrestrial$551,928
U19 · FY2017 · AI · contact PI
Mechanism of Action$520,297
U19 · FY2017 · AI
Identification of novel secondary metabolites produced by symbiotic Proteobacte$475,202
U19 · FY2017 · AI
Metabolomics driven discovery of drug leads from symbiotic bacteria$474,083
U19 · FY2017 · AI
In Vivo CORE$369,870
U19 · FY2017 · AI
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates$142,856
U19 · FY2017 · TW · contact PI
Admin-Core-001$140,572
U19 · FY2017 · AI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities$3,190,133
U19 · FY2016 · AI
In Vitro Core$655,151
U19 · FY2016 · AI
Discovering Antimicrobial Drugs from Symbiotic Actinobacteria from Terrestrial$553,948
U19 · FY2016 · AI · contact PI
Mechanism of Action$517,287
U19 · FY2016 · AI
Identification of novel secondary metabolites produced by symbiotic Proteobacte$475,202
U19 · FY2016 · AI
Metabolomics driven discovery of drug leads from symbiotic bacteria$475,093
U19 · FY2016 · AI
In Vivo CORE$369,870
U19 · FY2016 · AI
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates$151,886
U19 · FY2016 · TW · contact PI
Admin Core$143,582
U19 · FY2016 · AI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities$3,329,683
U19 · FY2015 · AI
In Vitro Core$810,360
U19 · FY2015 · AI
Identification of novel secondary metabolites produced by symbiotic Proteobacte$649,768
U19 · FY2015 · AI
Discovering Antimicrobial Drugs from Symbiotic Actinobacteria from Terrestrial$509,725
U19 · FY2015 · AI · contact PI
Mechanism of Action$447,425
U19 · FY2015 · AI
In Vivo CORE$390,733
U19 · FY2015 · AI
Metabolomics driven discovery of drug leads from symbiotic bacteria$368,824
U19 · FY2015 · AI
Admin Core$152,848
U19 · FY2015 · AI
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates$114,386
U19 · FY2015 · TW · contact PI
Antimicrobial Drug Discovery from Coevolved Symbiotic Communities$3,433,302
U19 · FY2014 · AI
In Vitro Core$885,209
U19 · FY2014 · AI
^Identification of novel secondary metabolites produced by symbiotic Proteobacte$641,924
U19 · FY2014 · AI
Discovering Antimicrobial Drugs from Symbiotic Actinobacteria from Terrestrial$503,572
U19 · FY2014 · AI · contact PI
Mechanism of Action$483,712
U19 · FY2014 · AI
Metabolomics driven discovery of drug leads from symbiotic bacteria$399,022
U19 · FY2014 · AI
In Vivo CORE$386,016
U19 · FY2014 · AI
Admin Core$133,847
U19 · FY2014 · AI
Novel therapeutic agents from the bacterial symbionts of Brazilian invertebrates$76,084
U19 · FY2014 · TW · contact PI
Discovery of natural product-based drugs from bacterial symbionts of insects$2,479,629
RC4 · FY2010 · GM · contact PI